Please assess the completion status of the following clinical trial:

Trial Title: Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must report currently smoke at least 10 cigarettes per day and been smoking for at least 1 year~* Must not be planning to quit smoking in the next 30 days, nor tried to quit in the last 30 days~* Must be able to read and speak English~* Should not concurrently using other tobacco products or nicotine medications~* Willing to try new tobacco products and substitute other brands of cigarettes~* Not current participating in any other ongoing research study~* Must be in good general health~* Medically eligible to receive nicotine replacement products (based upon the New York State \[NYS\] Smokers Quit line eligibility criteria)~  * No history of heart attack or stoke in last 2 weeks~ * No current use of Zyban, bupropion, Wellbutrin, or Chantix/varenicline, or other smoking cessation medication~ * No history of chest pains or angina in past month~ * No report of physician diagnosed arrhythmia/irregular heartbeat, fast heartbeat, abnormal heart rate, or use of pacemaker~ * No current report of physician diagnosed heart disease/coronary artery disease, high blood pressure (systolic blood pressure \[SBP\] = 160; diastolic blood pressure \[DBP\] = 100), stomach ulcer, diabetes, or taking pills for depression or asthma~ * No self-reported chronic dental problems that would interfere with using oral products~ * No use of an electronic cigarette (e-cigarette) in the past 30 days~ * No known sensitivity to glycerol, propylene glycol, or glycerin~* For females, not currently pregnant or breastfeeding; nor planning to become pregnant during the follow-up interval~* Prospective participants must also pass screening tests for substance use, administered at the orientation session, to be entered on study; substance use will be assessed using a Clinical Laboratory Improvement Amendments (CLIA)-waived 7-drug urine screen (detecting presence of tetrahydrocannabinol \[THC\], opiates, amphetamine, barbiturates, methamphetamine, phencyclidine \[PCP\], and lysergic acid diethylamide \[LSD\]); participants must test negative on all 7 to be put on study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (fixed rate ST product prices) (Type: EXPERIMENTAL): Participants purchase ST products using a fixed rate of product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks
- Arm II (escalating ST product prices) (Type: EXPERIMENTAL): Participants purchase ST products using escalating product prices once weekly and record their consumption of ST products and cigarettes smoked daily for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues